Skip to main content

Advertisement

SpringerLink
Log in

99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Scintigraphy with 99mTc-depreotide, a somatostatin analogue–technetium ligand, has been used for evaluation of various malignant neoplasms, including lung cancer. The diagnosis of bone metastases in patients with lung cancer is not always definitive with current imaging methods. Visualisation of somatostatin receptors (SSTRs) in bone lesions, when the primary tumour exhibits such receptors, could be helpful in characterising them as metastatic. The aim of this study was to assess the value of 99mTc-depreotide in differentiating between benign and malignant bone lesions in patients with lung cancer.

Methods

The study population comprised 20 patients (17 males and three females, mean age 63 years) with proven lung cancer in whom bone lesions had been detected by conventional imaging methods. All patients underwent 99mTc-hydroxydiethylene diphosphonate and 99mTc-depreotide scintigraphy within 2 weeks. Bone lesions were classified as benign or malignant on the basis of clinical, imaging and/or histological criteria.

Results

99mTc-depreotide uptake in the primary tumour was seen in 19 of the 20 patients. Conventional imaging methods detected 55 bone lesions, 31 of which were classified as malignant. Twenty-eight (90%) of these lesions showed 99mTc-depreotide uptake, suggesting bone metastases, while three did not. Twenty-four bone lesions were classified as benign by conventional imaging methods, and none of them showed 99mTc-depreotide uptake. In addition, 99mTc-depreotide demonstrated extra-osseous lesions in six patients.

Conclusion

In patients with lung cancer and bone lesions, 99mTc-depreotide scintigraphy uptake in the bone lesions supports the diagnosis of malignancy, in particular if the primary lung tumour also exhibits SSTRs. Furthermore, whole-body 99mTc-depreotide scintigraphy may disclose extra-osseous disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5a–c
Fig. 6a,b

Similar content being viewed by others

References

  1. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003;123:21S–49S

    PubMed  Google Scholar 

  2. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer 2003;41:245–58

    Article  PubMed  Google Scholar 

  3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23–47

    PubMed  Google Scholar 

  4. Bach PB, Niewoehner DE, Black WC. Screening for lung cancer: the guidelines. Chest 2003;123:83S–8S

    Article  PubMed  Google Scholar 

  5. Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD, American College of Chest Physicians. The solitary pulmonary nodule. Chest 2003;123:89S–96S

    Article  PubMed  Google Scholar 

  6. Valkema R, Steens J, Cleton FJ, Pauwels EK. The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 1996;122:513–32

    CAS  PubMed  Google Scholar 

  7. O’Byrne KJ, Carney DN. Radiolabeled somatostatine analogue scintigraphy in oncology. Anticancer Drugs 1996;7:33–4

    CAS  Google Scholar 

  8. Kwekkeboom DJ, Kho GS, Lamberts SW, Reubi JC, Laissue JA, Krenning EP. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;221:1106–13

    Google Scholar 

  9. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Paugerf T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. New trends in peptide receptor radioligands. Q J Nucl Med 2001;45:153–9

    CAS  PubMed  Google Scholar 

  10. Blum J, Handmaker H, Lister-James J, Rinne N. A multicenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232–8

    CAS  PubMed  Google Scholar 

  11. Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 1996;37:1016–22

    CAS  PubMed  Google Scholar 

  12. Grewal RK, Dadparvar S, Yu JQ, Babaria CJ, Cavanaugh T, Sherman M, Jacobstein J. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400–4

    PubMed  Google Scholar 

  13. Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des 2002;8:1827–36

    CAS  PubMed  Google Scholar 

  14. Morehead RS, Shih WJ. Tc-99m-labeled somatostatin receptor-binding peptide imaging for a pulmonary nodule. Clin Nucl Med 2001;26:910–2

    Article  CAS  PubMed  Google Scholar 

  15. Reubi JC, Schaer JC, Markwalder R, Waser B, Horisberger U, Laissue J. Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potencial relevance. Yale J Biol Med 1997;70:471–9

    CAS  Google Scholar 

  16. Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP, Lamberts SW. Somatostatin analogue scintigraphy in carcinoid tumours. Eur J Nucl Med 1993;20:283–92

    CAS  PubMed  Google Scholar 

  17. Leitha T, Meghdadi S, Studnicka M, Wolzt M, Marosi C, Angelberger P, Neumann M, Schlick W, Kletter K, Dudczak R. The role of iodine-123-Tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1993;34:1397–402

    CAS  PubMed  Google Scholar 

  18. Breeman WA, De Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser YJ, Krenning EP. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9

    CAS  PubMed  Google Scholar 

  19. Traub T, Petkov V, Ofluoglu S, Pangerl T, Raderer M, Fueger BJ, Schima W, Kurtaran A, Dudczak R, Virgolini I. 111In-DOTA-lanreotide scintigraphy in patient with tumors of the lung. J Nucl Med 2001;42:1309–15

    CAS  PubMed  Google Scholar 

  20. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med 2002;32:92–6

    Article  PubMed  Google Scholar 

  21. Reisinger I, Bohuslavitzki KH, Brenner W, Braune S, Dittrich I, Geide A, Kettner B, Otto HJ, Schmidt S, Munz DL. Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study. J Nucl Med 1998;39:224–7

    CAS  PubMed  Google Scholar 

  22. Stokkel MP, Kwa BM, Pauwels EK. Imaging and staging of small-cell lung cancer: is there a future role for octreotide scintigraphy? Br J Clin Pract 1995;49:235–8

    CAS  PubMed  Google Scholar 

  23. Fujita T, Yamaji Y, Sato M, Murao K, Takahara J. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2 in human lung cancer lines. Life Sci 1994;55:1797–806

    Article  CAS  PubMed  Google Scholar 

  24. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99m Tc-P829. Cancer Res 1998;58:1850–9

    CAS  PubMed  Google Scholar 

  25. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. Int J Clin Pract 2003;57:184–6

    CAS  PubMed  Google Scholar 

  26. Scutellari PN, Antinolfi G, Galeotti R, Giganti M. Metastatic bone disease. Strategies for imaging. Minerva Med 2003;94:77–90

    CAS  PubMed  Google Scholar 

  27. Nakamoto Y, Osman M, Wahl RL. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG. Clin Nucl Med 2003;28:302–7

    Article  PubMed  Google Scholar 

  28. Kahn D, Menda Y, Kernstine K, Bushnell D, Mclaughlin K, Miller S, Berbaum K. The utility of 99mTc-depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494–501

    Article  CAS  PubMed  Google Scholar 

  29. Zuetenhorst JM, Hoefnagel CA, Boot H, Valdés-Olmos RA, Taal BG. Evaluation of 111In-pentetreotide, 131I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002;23:735–41

    Article  CAS  PubMed  Google Scholar 

  30. Lebtahi R, Cadiot G, Delahaye N, Genin R, Daou D, Peker MC, Chosidow D, Faraggi M, Mignon M, Le Guludec D. Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999;40:1602–8

    CAS  PubMed  Google Scholar 

  31. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, Serrano J, Venzon DJ, Jensen RT. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location and effect of their detection on management. J Clin Oncol 1998;16:1040–53

    CAS  Google Scholar 

  32. Steger W, Amthauer H, Vogl TJ, Wiedenmann B, Steger S, Eichstadt H. Detection of bone metastases in patients with neuroendocrine gastrointestinal tumors. Radiologe 1999;39:235–40

    Article  CAS  PubMed  Google Scholar 

  33. Van de Wiele C, Signore A, Dierckx RA. Peptide receptor imaging: advances in the diagnosis of pulmonary diseases. Am J Respir Med 2002;1:177–83

    PubMed  Google Scholar 

  34. Vanhagen PM, krenninf EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, Laissure I, Hoogstede HC, Lamberts SW. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med 1994;21:497–502

    CAS  PubMed  Google Scholar 

  35. Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ. Distinct subsets of somatostatin receptors on cultured human lymphocytes. J Biol Chem 1989;264:497–502

    Google Scholar 

  36. Krenning EP, Kwekkeboom DJ, Bakker W. Somatostatin receptor scintigraphy with In-111-DTPA-d-Phe1 and I-131-Try-3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31

    CAS  PubMed  Google Scholar 

  37. Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med 2002;32:276–92

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Sant Pau Hospital, Pare Claret 167, 08025, Barcelona, Spain

    Esther Mena, Valle Camacho, Montserrat Estorch, Jordi Fuertes, Albert Flotats & Ignasi Carrió

Authors
  1. Esther Mena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valle Camacho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Montserrat Estorch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jordi Fuertes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Albert Flotats
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ignasi Carrió
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Mena.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mena, E., Camacho, V., Estorch, M. et al. 99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer. Eur J Nucl Med Mol Imaging 31, 1399–1404 (2004). https://doi.org/10.1007/s00259-004-1594-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1594-x

Keywords

Search

Navigation